Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is named one of the best small-cap biotech stocks to buy by analysts, with significant upside potential. JPMorgan reduces price target to $33 while maintaining an “Overweight” rating on November 12, 2025.

In Q3 2025, Syndax Pharmaceuticals reports a 21% revenue increase to $45.9 million, driven by strong sales of lead therapies like Revuforj and Niktimvo. The company ends the quarter with $456 million in cash and narrows net loss to $60.7 million.

Syndax Pharmaceuticals focuses on developing targeted therapies for rare and difficult-to-treat cancers. Despite potential investment appeal, other AI stocks may offer greater upside potential and less downside risk according to analysts.

Looking ahead, Syndax Pharmaceuticals projects total R&D costs of $380 to $385 million for the full year. The company’s strong financial position supports ongoing operations and pipeline development towards profitability.

Read more at Yahoo Finance: JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating